Contributions from emerging transcriptomics technologies and computational strategies for drug discovery.

Area of Science:

• Oncology and Pharmacology
• Genomics and Bioinformatics
• Systems Biology

Background:

• Drug discovery is a lengthy, complex process, especially for heterogeneous diseases like cancer.
• Conventional screening methods struggle with tumor subpopulations and diverse mutations.
• Drug repositioning offers a viable strategy for identifying new therapeutic applications.

Purpose of the Study:

• To explore advanced strategies for drug discovery in complex diseases.
• To highlight the role of computational methods and '-omics' data in modern drug development.
• To emphasize the importance of genomic variations in personalized medicine.

Main Methods:

• Leveraging high-throughput and deep sequencing technologies for '-omics' data generation.
• Employing computational methods and systems biology to interpret pharmacogenomic data.
• Utilizing genome-wide association studies (GWAS) to link genomic variations with drug response.

Main Results:

• '-Omics' data provides insights into molecular mechanisms of drug action.
• Computational approaches aid in interpreting complex pharmacogenomic datasets.
• Genomic variations are associated with differential drug responses among individuals.

Conclusions:

• Integrating multi-omics data and computational approaches is crucial for efficient drug discovery.
• Drug repositioning, aided by advanced technologies, can identify novel therapeutic uses.
• Genomic insights are fundamental for advancing personalized medicine in drug development.